LFCR•Lifecore Biomedical reported third-quarter revenue of $25.3 million, below the $26.7 million analyst estimate, as CDMO and HA manufacturing revenue fell 18% and 19% year over year. Its net loss widened to $40.1 million.
Lifecore Biomedical’s third-quarter revenue fell 19% year over year to $25.3 million, missing the $26.7 million consensus estimate. The company reported a net loss of $40.1 million, wider than a year earlier.
Lifecore secured two technology transfer projects in the quarter and three new development-phase programs early in the fourth quarter. The company expects new business wins to contribute to revenue growth starting in 2027.
